European CHMP Adopts Positive Opinion for Gilead Sciences’ Sovald for the Treatment of Chronic Hepatitis C Infection

27-11-2013 Business Wire HealthComments (0)

Antibiotics and Infectious diseasesGilead SciencesPharmaceuticalSovaldi

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorisation Application (MAA) for Sovaldi® (sofosbuvir 400 mg tablets), an investigational once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection in adult

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top